Medical Hypotheses
Volume 58, Issue 2 , Pages 115-119 , February 2002

Spontaneous regression: a hidden treasure buried in time

  • S.A. Hoption Cann

      Affiliations

    • Special Development Laboratory, Royal Jubilee Hospital, Victoria, British Columbia, Canada
    • Department of Biology, University of Victoria, Victoria, British Columbia, Canada
    • Department of Health Care and Epidemiology, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • J.P. van Netten

      Affiliations

    • Special Development Laboratory, Royal Jubilee Hospital, Victoria, British Columbia, Canada
    • Department of Biology, University of Victoria, Victoria, British Columbia, Canada
    • ,
  • C. van Netten

      Affiliations

    • Department of Health Care and Epidemiology, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • D.W. Glover

      Affiliations

    • Special Development Laboratory, Royal Jubilee Hospital, Victoria, British Columbia, Canada

Received 12 February 2001 ,Accepted 5 July 2001.

References 

  1. Forni G, Lollini PL, Musiani P, Colombo MP. Immunoprevention of cancer: is the time ripe?. Cancer Res. 2000;60:2571–2575
  2. Nauts, H. C. The Beneficial Effects of Bacterial Infections on Host Resistance to Cancer: End Results in 449 Cases, 2nd edn. Monograph No. 8, New York, Cancer Research Institute, 1980.
  3. Le Dran HF. Traité des opérations de chirurgie. Paris: C. Osmont; 1742;
  4. Trnka V. History of remittent fevers. Vienna: Vindobonae; 1783;
  5. Quesnay F. Traité de la gangrène. Paris: d'Houry; 1749; p. 313
  6. White G. Letter XVIII to Thomas Pennant, 27 July 1768. The Natural History of Selborne. London: G. Routledge and Sons; 1890; p. 56
  7. Goldsmith O. An history of the frog kind. An history of the earth and animated nature. 7. London: J Nourse; 1774; p. 102–107
  8. Pennant T. British Zoology. London: Warrington; 1777; p. 338–344
  9. Amoureaux A. On the internal usage of belladonna. J Med Chir Pharm. 1760;13:47–65
  10. Dupré de Lisle M. Treatise on the cancer disease. Paris: Couturier; 1774;
  11. Vautier A. H. General perspectives on the cancer illness, Thèse du Paris, 1813, No. 43.
  12. Verneuil A. Inoculation of erysipelas as a means of cure. Union Med (Paris). 1886;41:19–22
  13. Thiery P. On fulguration in cancer. Bull Mem Soc Chir Paris. 1909;35:604–698
  14. Rovighi A. Cancer and malaria. Lavori Cong Med Int (Rome). 1903;12:202–204
  15. Alquié A. Syphilis inoculation in cancer. Gaz Hop. 1851;24:546
  16. Didot A. Essai sur la prophylaxie du cancer par la syphilization artificielle. Bull Acad R Med Belg 1851. 1852;11:100–172
  17. Tanchou, S. Research on the medical treatment of cancerous tumors of the breast, work based on three centuries of observations (extracts from a large number of authors), Paris, G. Baillière, 1844.
  18. Walshe WH. The nature and treatment of cancer. London: Taylor and Walter; 1844;
  19. Cruveilhier J. General treatise on pathological anatomy. Paris: J.B., Baillière; 1864; p. 251
  20. Lister J. The collected papers of Joseph, Baron Lister. Oxford: Clarendon Press; 1906;
  21. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci. 1893;105:487–511
  22. Nauts HC, Fowler GA, Bogatko FH. A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumours in man. Acta Med Scand Suppl. 1953;276:1–103
  23. Beebe SP, Tracy M. The treatment of experimental tumors with bacterial toxins. JAMA. 1907;49:1493–1498
  24. Coley WB. Late results of the treatment of inoperable sarcoma by the mixed toxins of erysipelas and Bacillus prodigiosus. Am J Med Sci. 1906;131:375–430
  25. Lamm DL, Blumenstein BA, Crissman JD. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol. 2000;163:1124–1129
  26. Mohr C. A case of carcinoma of the breast vs. erysipelas and arsenic. North Am J Homeop. 1888;3:700–702
  27. Richardson MA, Ramirez T, Russell NC, Moye LA. Coley toxins immunotherapy: a retrospective review. Altern Ther Health Med. 1999;5:42–47
  28. Brivio F, Lissoni P, Fumagalli L. Pre-operative IL-2 immunoprophylaxis of cancer recurrence: long-term clinical results of a phase II study in radically operable colorectal cancer. Oncol Rep. 1999;6:1205–1207
  29. Rosenstein DL, Lerner D, Cai J. More on the depressive effects of interferon alfa. N Engl J Med. 1999;341:849–850
  30. Vermorken JB, Claessen AME, van Tinteren H. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet. 1999;353:345–350
  31. Yano T, Sugio K, Yamazaki K. Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer. Lung Cancer. 1999;26:143–148
  32. Bowles AP, Perkias E. Long-term remission of malignant brain tumors after intracranial infection: a report of four cases. Neurosurgery. 1999;44:636–642
  33. Garcia-Rayo S, Gurpide A, Vega F, Brugarolas A. Spontaneous tumor regression in a patient with multiple myeloma: report of another case. Rev Med Univ Navarra. 1996;40:41–42
  34. Ruckdeschel JC, Codish SD, Stranahan A, McNeally MF. Postoperative empyema improves survival in lung cancer: documentation of a natural experiment. N Engl J Med. 1972;287:1013–1017
  35. Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y. Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol. 2000;7:263–269
  36. Salvesen HB, Akslen LA. Significance of tumor-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumor angiogenesis and prognosis in endometrial carcinomas. Int J Cancer. 1999;84:538–543
  37. van Netten JP, Ashmead BJ, Cavers D. Macrophages and their putative significance in human breast cancer. Br J Cancer. 1992;66:220–221
  38. Oleszczuk JJ, van Netten JP, Ross AS. Biological aspects of breast cancer metastasis: consequences of tumor cell/macrophage interactions. Klin Perinatol Ginecol. 1994;12:215–221
  39. van Netten JP, Cann SA. Compression mammography and breast cancer: should pain be ignored?. Cancer J. 1996;9:278–279
  40. Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol. 1998;64:275–290
  41. Takahashi Y, Bucana CD, Liu W. Platelet-derived growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst. 1996;88:1146–1151
  42. Takanami I, Takeuchi K, Kodaira S. Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology. 1999;57:138–142
  43. van Netten JP, George EJ, Ashmead BJ. Macrophage-tumor cell associations: a factor in metastasis of breast cancer?. J Leukoc Biol. 1993;54:360–362
  44. Williams WR. The influence of other diseases upon cancer. Edinburgh Med J. 1898;4:334–337
  45. Carlson HA, Bell ET. A statistical study of the occurrence of cancer and tuberculosis in 11,195 post mortem examinations. J Cancer Res. 1929;13:126–135
  46. Dalgleish AG. Cancer vaccines. Br J Cancer. 2000;82:1619–1624
  47. Lee K-H, Wang E, Nielsen M-B. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol. 1999;163:6292–6300

PII: S0306-9877(01)91469-0

doi: 10.1054/mehy.2001.1469

Medical Hypotheses
Volume 58, Issue 2 , Pages 115-119 , February 2002

Article Tools